Pathophysiology of cardiotoxicity from target therapy and angiogenesis inhibitors

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Journal of Cardiovascular Medicine

• Publication date

  2016-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.2459/JCM.0000000000000377PMID 27183521
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Improving the preclinical models for the study of chemotherapy-induced cardiotoxicity: a Position Paper of the Italian Working Group on Drug Cardiotoxicity and Cardioprotection

  2015cited by this paper
• Feasibility and cardiac safety of trastuzumab emtansine after anthracycline-based chemotherapy as (neo)adjuvant therapy for human epidermal growth factor receptor 2-positive early-stage breast cancer.

  2015cited by this paper
• Patterns of cardiac toxicity associated with irreversible proteasome inhibition in the treatment of multiple myeloma.

  2015cited by this paper
• Conquests and perspectives of cardio-oncology in the field of tumor angiogenesis-targeting tyrosine kinase inhibitor-based therapy

  2015cited by this paper
• Chemotherapy-induced cardiotoxicity: detection, prevention, and management.

  2014cited by this paper
• Antagonism of Sorafenib and Regorafenib actions by platelet factors in hepatocellular carcinoma cell lines

  2014cited by this paper
• Common questions regarding clinical use of axitinib in advanced renal cell carcinoma.

  2014cited by this paper
• Correction: Trastuzumab Alters the Expression of Genes Essential for Cardiac Function and Induces Ultrastructural Changes of Cardiomyocytes in Mice

  2014cited by this paper
• Trastuzumab Emtansine: A Review of Its Use in Patients with HER2-Positive Advanced Breast Cancer Previously Treated with Trastuzumab-Based Therapy

  2014cited by this paper
• Trastuzumab-containing regimens for metastatic breast cancer.

  2014cited by this paper
• Ranolazine protects from doxorubicin‐induced oxidative stress and cardiac dysfunction

  2014cited by this paper
• QTc interval prolongation with vascular endothelial growth factor receptor tyrosine kinase inhibitors

  2014cited by this paper
• Cardiovascular toxicity of biologic agents for cancer therapy.

  2014cited by this paper
• Cardiotoxicity Associated with the Tyrosine Kinase Inhibitor Sunitinib

  2013cited by this paper
• Trastuzumab Alters the Expression of Genes Essential for Cardiac Function and Induces Ultrastructural Changes of Cardiomyocytes in Mice

  2013cited by this paper
• Cardiac complications and manifestations of chemotherapy for cancer

  2013cited by this paper
• Risk of Heart Failure in Breast Cancer Patients After Anthracycline and Trastuzumab Treatment: A Retrospective Cohort Study

  2012cited by this paper
• Mechanisms of cardiotoxicity associated with ErbB2 inhibitors

  2012cited by this paper
• Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.

  2012cited by this paper
• Notch signaling and cardiac repair.

  2012cited by this paper
• High-sensitivity C-reactive protein (hs-CRP) as a biomarker for trastuzumab-induced cardiotoxicity in HER2-positive early-stage breast cancer: a pilot study

  2012cited by this paper
• Evaluation of the effect of food on the pharmacokinetics of axitinib in healthy volunteers

  2012cited by this paper
• Thyroid dysfunction from antineoplastic agents.

  2011cited by this paper
• Trastuzumab-induced cardiac dysfunction: A 'dual-hit'.

  2011cited by this paper
• Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.

  2011cited by this paper
• Cardiotoxicity in patients treated with bevacizumab is potentially reversible.

  2011cited by this paper
• Regorafenib (BAY 73‐4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity

  2011cited by this paper
• Cardiovascular effects of systemic cancer treatment.

  2011cited by this paper
• Cardiomyocyte PDGFR-beta signaling is an essential component of the mouse cardiac response to load-induced stress.

  2010cited by this paper
• Angiotensin converting enzyme inhibitors may be protective against cardiac complications following anthracycline chemotherapy

  2010cited by this paper
• The vulnerability of the heart as a pluricellular paracrine organ: lessons from unexpected triggers of heart failure in targeted ErbB2 anticancer therapy.

  2010cited by this paper
• Inhibition of ErbB2 by Herceptin reduces viability and survival, induces apoptosis and oxidative stress in Calu-3 cell line

  2010cited by this paper
• Cardiovascular safety of VEGF-targeting therapies: current evidence and handling strategies.

  2010cited by this paper
• Troponin I provides insight into cardiotoxicity and the anthracycline-trastuzumab interaction.

  2010cited by this paper
• Trastuzumab versus lapatinib: the cardiac side of the story.

  2009cited by this paper
• Sunitinib‐Induced Cardiotoxicity Is Mediated by Off‐Target Inhibition of AMP‐Activated Protein Kinase

  2009cited by this paper
• Cardiotoxicity associated with trastuzumab treatment of HER2+ breast cancer

  2009cited by this paper
• Intricacies of Bevacizumab-Induced Toxicities and Their Management

  2009cited by this paper
• Cardiotoxicity Profile of Trastuzumab

  2008cited by this paper
• Targeted therapies for metastatic renal cell carcinoma: an overview of toxicity and dosing strategies.

  2008cited by this paper
• Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials.

  2008cited by this paper
• Mechanisms of Myocyte Cytotoxicity Induced by the Multiple Receptor Tyrosine Kinase Inhibitor Sunitinib

  2008cited by this paper
• Anthracycline-trastuzumab regimens for HER2/neu-overexpressing breast cancer: current experience and future strategies.

  2008cited by this paper
• Sorafenib in advanced clear-cell renal-cell carcinoma.

  2007cited by this paper
• Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.

  2007cited by this paper
• 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial.

  2007cited by this paper
• Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition

  2007cited by this paper
• Attenuation of doxorubicin-induced contractile and mitochondrial dysfunction in mouse heart by cellular glutathione peroxidase.

  2006cited by this paper
• Mechanisms of hypertension associated with BAY 43-9006.

  2006cited by this paper
• Bortezomib or high-dose dexamethasone for relapsed multiple myeloma.

  2005cited by this paper
• Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity.

  2005cited by this paper
• Clinical cardiac tolerability of trastuzumab.

  2004cited by this paper
• Targeted Disruption of hesr2 Results in Atrioventricular Valve Anomalies That Lead to Heart Dysfunction

  2004cited by this paper
• Trastuzumab‐associated cardiotoxicity

  2002cited by this paper
• ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases.

  2002cited by this paper
• Angiotensin II type 1a receptor mediates doxorubicin-induced cardiomyopathy.

  2002cited by this paper
• ErbB2 is essential in the prevention of dilated cardiomyopathy

  2002cited by this paper
• Cardiac dysfunction in the trastuzumab clinical trials experience.

  2002cited by this paper
• Novel 4-anilinoquinazolines with C-7 basic side chains: design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors.

  2002cited by this paper
• Human carbonyl reductase overexpression in the heart advances the development of doxorubicin-induced cardiotoxicity in transgenic mice.

  2000cited by this paper
• Herceptin (trastuzamab) in advanced breast cancer.

  2000cited by this paper
• Myocyte survival pathways and cardiomyopathy: implications for trastuzumab cardiotoxicity.

  2000cited by this paper
• The potential for QT prolongation and pro-arrhythmia by non-anti-arrhythmic drugs: clinical and regulatory implications. Report on a Policy Conference of the European Society of Cardiology.

  2000cited by this paper
• Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.

  1987cited by this paper

• Associations of cardiovascular–kidney–metabolic syndrome stages with long-term mortality among US cancer survivors: a prospective cohort study

  2026cites this paper
• Vulnerable plaques in atherosclerosis: focus on angiogenesis-associated phenotypic crosstalk

  2026cites this paper
• Anti-inflammatory Pathways of Novel Anti-diabetic Therapies. A Literature Review

  2026cites this paper
• Mechanism of tilapia skin antioxidant pentapeptide on atherosclerosis: Inhibition of angiogenesis and oxidative stress

  2025cites this paper
• Acute cardiac dysfunction in patients with ovarian cancer treated with Niraparib due to TFAM mutation: A case series and functional analysis.

  2025cites this paper
• In the Era of Cardiovascular–Kidney–Metabolic Syndrome in Cardio-Oncology: From Pathogenesis to Prevention and Therapy

  2025cites this paper
• Acute vascular and cardiac effects of lenvatinib in mice

  2025cites this paper
• Chemotherapy-Induced Cardiotoxicity: Mechanisms, Detection and Emerging Therapies in Cardio-Oncology

  2025cites this paper
• Heartbreakers and healers: RNA rebels in cardio-oncology

  2025cites this paper
• Major Adverse Cardiovascular Events in Angiogenesis Inhibitor‐Based Cancer Therapy: A Systematic Review and Meta‐Analysis

  2025cites this paper
• Transient Left Ventricular Dysfunction from Cardiomyopathies to Myocardial Viability: When and Why Cardiac Function Recovers

  2024cites this paper
• Pharmacoproteogenomic approach identifies on-target kinase inhibitors for cancer drug repositioning

  2024cites this paper
• Cancer and Heart Failure: Dangerous Liaisons

  2024cites this paper
• The role of Epsins in atherosclerosis: From molecular mechanisms to therapeutic applications.

  2024cites this paper
• Efficacy and safety of ramucirumab for gastric or gastro-esophageal junction adenocarcinoma: a systematic review and meta-analysis

  2024cites this paper
• Cardiovascular toxicity in antitumor therapy: biological and therapeutic insights.

  2024cites this paper
• Atrioventricular re-entrant tachycardia and atrioventricular node re-entrant tachycardia in a patient with cancer under chemotherapy: a case report and literature review

  2024cites this paper
• Association of angiogenesis-associated genes with atherosclerotic plaque progression, intraplaque hemorrhage, and immune infiltration

  2024cites this paper
• Identification of cardiotoxicity related to non-small cell lung cancer (NSCLC) treatments: A systematic review

  2023cites this paper
• VEGF (Vascular Endothelial Growth Factor) Inhibition and Hypertension: Does Microvascular Rarefaction Play a Role?

  2023cites this paper
• Cardiovascular Toxicity Induced by Vascular Endothelial Growth Factor Inhibitors

  2023cites this paper
• Identification of a Novel Angiogenesis Signalling circSCRG1/miR-1268b/NR4A1 Pathway in Atherosclerosis and the Regulatory Effects of TMP-PF In Vitro

  2023cites this paper
• Role of Arterial Hypertension and Hypertension-Mediated Organ Damage in Cardiotoxicity of Anticancer Therapies

  2023cites this paper
• Cardiovascular Complications of Pan-Cancer Therapies: The Need for Cardio-Oncology

  2023cites this paper
• Paris saponin Ⅰ induce toxicity in zebrafish by up-regulation of p53 pathway and down-regulation of wnt pathway.

  2023cites this paper
• The effect of propolis on 5-fluorouracil-induced cardiac toxicity in rats

  2022cites this paper
• Mechanism of two alkaloids isolated from coral endophytic fungus for suppressing angiogenesis in atherosclerotic plaque in HUVEC.

  2022cites this paper
• Protective effects and mechanisms of lycorine against adriamycin-induced cardiotoxicity.

  2022cites this paper
• Cardiotoxicity of Biological Therapies in Cancer Patients: An In-depth Review

  2022cites this paper
• Risk of hypertension with anti-VEGF monoclonal antibodies in cancer patients: a systematic review and meta-analysis of 105 phase II/III randomized controlled trials

  2021cites this paper
• Structure–activity relationships and drug design

  2021cites this paper
• Cardiotoxic effects of angiogenesis inhibitors

  2021cites this paper
• Cardiac assessment in Australian patients receiving (neo)adjuvant trastuzumab for HER2-positive early breast cancer: a population-based study

  2021cites this paper
• The Molecular Mechanisms of Cardiotoxicity Induced by HER2, VEGF, and Tyrosine Kinase Inhibitors: an Updated Review

  2021cites this paper
• ANTI-INFLAMMATORY AND PROTECTIVE EFFECT OF THE SEED OF TETRACARPIDIUM CONOPHORUM (AFRICAN WALNUT) ON WISTAR RATS WITH DOXORUBICIN INDUCED CARDIOTOXICITY

  2021cites this paper
• The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin

  2021cites this paper
• Reasons why COVID-19 survivors should follow dietary World Cancer Research Fund/American Institute for Cancer Research (WCRF/AICR) recommendations: from hyper-inflammation to cardiac dysfunctions.

  2021cites this paper
• Polydatin Reduces Cardiotoxicity and Enhances the Anticancer Effects of Sunitinib by Decreasing Pro-Oxidative Stress, Pro-Inflammatory Cytokines, and NLRP3 Inflammasome Expression

  2021cites this paper
• ATVB IN FOCUS: Cardiovascular Effects of Anticancer Treatments/Agents

  2021cites this paper
• Vascular endothelial growth factor modulates pulmonary vein arrhythmogenesis via vascular endothelial growth factor receptor 1/NOS pathway.

  2021cites this paper
• Mechanism and prevention strategy of a bidirectional relationship between heart failure and cancer (Review)

  2021cites this paper
• Heart Failure Therapies for the Prevention of HER2-Monoclonal Antibody-Mediated Cardiotoxicity: A Systematic Review and Meta-Analysis of Randomized Trials

  2021cites this paper
• Cardiovascular toxicity induced by chemotherapy and target drugs: mechanisms, diagnostic and preventive approaches

  2021influential citation
• Pazopanib-induced fatal heart failure in a patient with unresectable soft tissue sarcoma and review of literature

  2020cites this paper
• SARS-CoV-2 Infection and Cardioncology: From Cardiometabolic Risk Factors to Outcomes in Cancer Patients

  2020cites this paper
• The support of genetic evidence for cardiovascular risk induced by antineoplastic drugs

  2020cites this paper
• The SGLT-2 inhibitor empagli�ozin improves myocardial strain, reduces cardiac �brosis and pro-inammatory cytokines in non-diabetic mice treated with doxorubicin

  2020cites this paper
• Trastuzumab increases pulmonary vein arrhythmogenesis through modulating pulmonary vein electrical and conduction properties via phosphatidylinositol 3-kinase signaling

  2020cites this paper
• Nano-Encapsulation of Coenzyme Q10 in Secondary and Tertiary Nano-Emulsions for Enhanced Cardioprotection and Hepatoprotection in Human Cardiomyocytes and Hepatocytes During Exposure to Anthracyclines and Trastuzumab

  2020cites this paper
• Shared biology, genetic and cellular molecular pathways

  2020cites this paper
• Bidirectional Relationship Between Cancer and Heart Failure: Old and New Issues in Cardio-oncology

  2019cites this paper
• Ozone Exerts Cytoprotective and Anti-Inflammatory Effects in Cardiomyocytes and Skin Fibroblasts after Incubation with Doxorubicin

  2019cites this paper
• Novel Human Bispecific Aptamer–Antibody Conjugates for Efficient Cancer Cell Killing

  2019cites this paper
• Potential Protective Effect of Achillea fragrantissima against Adriamycin-Induced Cardiotoxicity in Rats via an Antioxidant and Anti-Inflammatory Pathway

  2019cites this paper
• Role of oxidative stress in cardiotoxicity of antineoplastic drugs.

  2019cites this paper
• Cardiotoxicity and pro-inflammatory effects of the immune checkpoint inhibitor Pembrolizumab associated to Trastuzumab.

  2019cites this paper
• Inhibition of vascular endothelial growth factor in young adult mice causes low bone blood flow and bone strength with no effect on bone mass in trabecular regions

  2019cites this paper
• Boswellic acid has anti‐inflammatory effects and enhances the anticancer activities of Temozolomide and Afatinib, an irreversible ErbB family blocker, in human glioblastoma cells

  2019cites this paper
• Association of pazopanib-induced toxicities with outcome of patients with advanced soft tissue sarcoma; a retrospective analysis based on the European Organisation for Research and Treatment of Cancer (EORTC) 62043 and 62072 clinical trials

  2019cites this paper
• Exploring pharmacological mechanisms of Xueshuan-Xinmai-Ning tablets acting on coronary heart disease based on drug target-disease gene interaction network.

  2019cites this paper
• Cardiac and Vascular Microenvironment: Biological and Clinical Implications in Cardiology

  2018cites this paper
• Cardiovascular Side Effects of Breast Cancer Therapy

  2018cites this paper
• Cardiovascular safety of oncologic agents: A double-edged sword even in the era of targeted therapies – part 1

  2018cites this paper
• Chemotherapy-induced cardiotoxicity: new insights into mechanisms, monitoring, and prevention

  2018cites this paper
• Cancer chemotherapy failure: a synthetic view

  2018cites this paper
• Pharmacogenetics of Chemotherapy-Induced Cardiotoxicity

  2018cites this paper
• Toxicity of cancer therapy: what the cardiologist needs to know about angiogenesis inhibitors

  2018cites this paper
• Cardioprotective Effects of Nanoemulsions Loaded with Anti-Inflammatory Nutraceuticals against Doxorubicin-Induced Cardiotoxicity

  2018cites this paper
• Fuxin decoction attenuates doxorubicin-induced heart failure in rats via oxidizing suppression and regulating immune responses

  2018cites this paper
• Angiogenesis in the atherosclerotic plaque

  2017cites this paper
• Microscopic evaluation of the ventricular tissue using stereological and Voronoi tessellation methods: Application on doxorubicin-induced cardiotoxicity in rats.

  2017cites this paper
• Impact and clinical significance of Embosphere microsphere artery embolization therapy in serum VEGF expression level of women patients with uterine fibroids.

  2017cites this paper